Area of research
Physiology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Asthma and respiratory diseases, Allergic Rhinitis and Sensitization, Chronic Obstructive Pulmonary Disease (COPD) Research, and Inhalation and Respiratory Drug Delivery.
Adipokines in Obese Asthma: A Complex Relationship Influenced More by Sex, Weight, and Oral Steroid Treatment Than Disease Severity
Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study
Allergic Rhinitis and Its Impact on Asthma ( <scp>ARIA</scp> )‐ <scp>EAACI</scp> Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments
Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma ( <scp>ARIA</scp> )‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making Algorithms
Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users
Impact of allergic symptoms on work productivity in allergic rhinitis: A MASK-air direct patient data study
Targeted Treatment in Asthma—Opportunities and Challenges
Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study
Asthma and rhinitis control in adolescents and young adults: A real‐world <scp>MASK</scp> ‐air study
Concurrent validity, cut‐offs and ability to change of patient‐reported outcome measures for rhinitis and asthma in MASK‐air<sup>®</sup>
Assessment of the underreporting of rhinitis in patients with asthma: A MASK-air® real-world study
Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study
Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis
Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air<sup>®</sup>approach
Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The <scp>ARIA‐EAACI</scp> approach – ARIA‐EAACI Task Force Report
Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
<scp>UCRAID</scp> (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme
Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app
Development and Validation of an Electronic Daily Control Score for Asthma (e-DASTHMA)
Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation
Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation
Short-acting ß2-agonists and greenhouse gas emissions in Europe and Canada
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study
National and regional asthma programmes in Europe
Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease
Frequent exacerbators - a distinct phenotype of severe asthma